25 results about "Therapeutic targeting" patented technology

The present invention provides methods of treating ischemic and traumatic central nervous system injury by administering an antagonist of the interaction between CD47 and SIRPa. Also provided are method of increasing efferocytosis after a traumatic or ischemic CNS injury by administering an antagonist of the interaction between CD47 and SIRPa.

The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a breast cancer or a pancreatic cancer). More specifically, the invention concerns the treatment of patients having cancer for the therapeutic inhibition of cancer cell growth and metastasis with an anti-Cadherin 11 monoclonal antibody with specific monoclonal antibody clones 23C6 or 3H10.

Metastasis is a major cause of fatality and expense in cancer. Many metastatic patients express calcified, fibrotic, or deep-seated (lymph / Jung / brain) lesions that are not easily profiled. For such patients, decision-making regarding treatment selection is population-based and heavily reliant on standards of care and are not tailored to the individual's tumor. The present disclosure provides methods of identifying treatment protocols for cancer patients using released tumor cells (RTCs). Method described herein include isolating / enriching RTCs, profiling RTCs and comparing RTCs to reference RTC profile libraries.

The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress / eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress / eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoids using the multiomics approach provide opportunities to unravel potential therapeutic targets for incurable retinal diseases, such as XLRS.

The invention discloses a xanthohumol lung cancer targeted therapy method based on an exosome delivery system and application of the xanthohumol lung cancer targeted therapy method, and relates to the technical field of biological medicine and drug targeted delivery, in particular to the xanthohumol lung cancer targeted therapy method based on the exosome delivery system and the application of the xanthohumol lung cancer targeted therapy method. The lemon-derived exosome is used as a carrier, so that the enrichment effect of xanthohumol in tumor tissues is effectively improved, and the anti-tumor effect of xanthohumol is enhanced; the xanthohumol regulates a lung cancer immune microenvironment by influencing an immune checkpoint PD-L1; wherein the immunomodulatory effect is optimized, the treatment effect is improved, and tumor-related immunosuppression is relieved; in order to solve the problem that the effect of a traditional xanthohumol delivery mode is limited, an exosome delivery platform is adopted, and the delivery efficiency and the treatment targeting property of the medicine are further improved by utilizing the natural targeting property and the low immunogenicity of the exosome delivery platform; through an intelligent delivery system, the toxicity of xanthohumol to normal tissues is reduced.

The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.

Disclosed are methods of treatment and inhibitors for gastrointestinal stromal tumor (GIST) in a subject, with an active agent that inhibits a Menin or a member of the Menin-MLL complex.

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46-overexpressing tumors.

A method of using an EDA2R inhibitor or an NIK inhibitor and an OSMR inhibitor for the treatment and / or prevention of the relevant disease is provided, where the treatment and / or prevention is performed by therapeutic targeting of newly discovered mechanisms causing skeletal muscle atrophy. The present invention also proposes methods for developing, preparing, and applying pharmaceutical formulations including the relevant inhibitors.

The invention provides a BRCA specific siRNA which is used for enhancing the sensitivity of cancer cells to a PARP inhibitor. According to the present invention, the siRNA can be combined with the PARP inhibitor to induce cancer cell death, and is suitable for patients having the wild-type BRCA gene and having the low treatment effect on the PARP inhibitor. According to the present invention, the fusion protein-siRNA complex for delivering the siRNA can be absorbed by cells through CD47 mediation, such that the fusion protein-siRNA complex can be specifically delivered to cancer cells, and can be efficiently absorbed by the cells so as to maximize the desired cell death effect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of DNA / RNA heterodouble-stranded oligonucleotide of SYK in preparation of a medicine for inhibiting intrahepatic cholangiocarcinoma (ICC) metastasis. The DNA / RNA heteroduplex oligonucleotide (SYK-HDO) of SYK disclosed by the invention is combined with a low-density lipoprotein receptor (LDLR) through cholesterol modification, so that ICC cells with high LDLR expression are specifically targeted, and the treatment targeting is improved; sYK-HDO is actively delivered to tumor cells by utilizing LDLR-mediated endocytosis, so that the local drug concentration is improved, and the drug administration frequency is reduced; in addition, due to the DNA-RNA double-strand structure of the polypeptide, the polypeptide is not easy to degrade by nuclease in blood circulation; and finally, the SYK-HDO can stably silence the expression of the SYK gene of the bile duct cancer cell line through a gene silencing mechanism, so that the possible off-target effect and drug resistance of the SYK kinase inhibitor can be avoided.

This invention relates to a method for preparing drug-loaded nanoparticles that regulate the tumor microenvironment. The steps include: S1, dispersing CaCO3 nanoparticles in a first solvent, adding dopamine hydrochloride solution, lysine solution, and ammonia, reacting for a first time, terminating the reaction, and separating the solid and liquid to obtain the first nanoparticles; S2, dispersing the first nanoparticles in a second solvent, adding alendronate sodium solution, adjusting the pH to neutral, reacting for a second time to obtain the second nanoparticles; S3, dispersing the second nanoparticles in a second solvent, adding dimethyl sulfoxide, shikonin solution, and dihydroporphyrin E6 solution, reacting for a third time, and separating the solid and liquid to obtain the drug-loaded nanoparticles. The drug-loaded nanoparticles of this invention can be used for multi-target therapy, targeting tumor cells. In addition to directly killing tumor cells with ROS generated by PDT and SHK, they induce ICD in cancer cells, reverse the acidic tumor microenvironment, and increase CD4+. + T cell infiltration and a reduction in Treg cells.

The application discloses a nano-focal anaphylaxis drug targeting CD47 protein and preparation and application thereof, and belongs to the technical field of drugs. The nano-focal anaphylaxis drug is a micellar nanoparticle formed by self-assembly of an amphiphilic carrier material and a focal anaphylaxis prodrug, the amphiphilic carrier material is composed of an amphiphilic polymer with a hydrophilic end modified with a CD47 targeting peptide and an amphiphilic polymer without modification, and the focal anaphylaxis prodrug is a prodrug formed by reduction response chemical bond connection of lonidamide or 3-bromopyruvic acid. The nano-focal anaphylaxis drug provided by the application can realize precise tumor treatment, the CD47 targeting peptide realizes efficient targeted delivery and accumulation of the drug in the tumor, the release of the focal anaphylaxis prodrug is triggered by higher reduction medium level in tumor tissues, and tumor cells are induced to undergo focal anaphylaxis. In normal tissues, the nano drug cannot induce normal cell focal anaphylaxis, and therefore the tumor selectivity of the nano drug is significantly enhanced.

The present invention relates to isolated antibodies, fragments thereof and antibody-drug conjugates that bind to Lymphocyte antigen 6 family member K (LY6K) and their use for screening for LY6K-positive malignant cells or for therapeutic targeting of LY6K-positive malignant cells.

The application belongs to the technical field of biological medicine, and discloses a spinal cord injury treatment drug based on a LINC00311 / miR-4318 / MYLK regulation axis and an application thereof, and aims to solve the technical problems of poor targeting and large side effects of the existing anti-inflammatory treatment of spinal cord injury. The effective component of the drug is an inhibitor of LINC00311, the inhibitor is selected from one or more of shRNA, siRNA, antisense oligonucleotide and CRISPRi system, can target the specific nucleotide sequence of LINC00311, and can be used in combination with miR-4318 mimic, and is administered by intrathecal injection, slow virus carrier delivery and the like. The in-vitro experiment proves that the inhibitor can significantly inhibit the release of TNF-alpha, IL-1beta, IL-6 and other pro-inflammatory factors by microglia cells; the in-vivo experiment shows that it can significantly improve the BBB motor function score of spinal cord injury rats, and reduce spinal cord tissue edema and necrosis. The application first discloses the mechanism of the LINC00311 / miR-4318 / MYLK ceRNA regulation axis in spinal cord injury, has the advantages of novel target, significant effect and high transformation potential, and provides a new scheme for the clinical treatment of spinal cord injury.

The present invention relates to an anti-CD38 antibody containing one or more mutations in the Fc region, and to the use of such an antibody in the treatment of a disease in a target, such as hematological malignancies.

Provided is a method for treatment of lung squamous cell carcinoma (LUSC) by administering to an individual in need of treatment one or more inhibitors of the RTK-Ras signaling pathway. The LUSC cells may carry a mutation in a KMT2D gene. The inhibitors of the RTK-Ras signaling pathway are SHP2 inhibitors or epidermal growth factor receptor (EGFR) inhibitors. Combinations of the SHP2 inhibitors and EGFR inhibitors can be used.

This invention relates to the field of bone repair materials technology, and discloses a bone repair material utilizing deer bone peptides and its preparation method. The method includes the preparation of deer bone extract, the preparation of melon seed extract, the formulation of a composite peptide solution, the preparation of a carrier base solution, and the compounding and molding. By using a composite peptide solution containing deer bone peptides and melon seed peptides, the synergistic effect of the two peptides enables the material to possess excellent osteoblast proliferation, differentiation, and anti-inflammatory activity, thereby promoting the repair and regeneration of bone defects and enhancing the bioactivity and therapeutic targeting of the material. By mixing the composite peptide solution with a carrier base solution containing a biocompatible carrier material and adding a cross-linking agent for cross-linking, a stable structure is formed between the peptides and the carrier material, thereby ensuring that the material has good mechanical support properties and a controllable degradation rate, ensuring that the material maintains its morphology in the early stages of implantation and guides new bone growth in an orderly manner over time.

The present invention relates to the use of prochlorazine, PCP, or an analog thereof for the treatment of cancer in an individual by modulating cancer cell membrane proteins and receptors and inducing alterations in the expression of cancer cells and extracellular surface markers produced by the cancer cells. The method of the invention provides a novel method for the treatment and diagnosis of cancer and cancer metastasis. The specific surface marker can be used as a potential candidate of cancer-related extracellular bodies (EVs), and has applicability in the aspects of diagnosis, prognosis and treatment targets.

The present invention relates to an anti-CLL1 single-domain antibody and its use. Specifically, it relates to a single-domain antibody having the amino acid sequence of SEQ ID NO: 1. The single-domain antibody of the present invention has high affinity and can specifically target CLL1-positive cells, and can be used to detect CLL1 expression in bone marrow cells of AML patients. The single-domain antibody of the present invention can be used to produce specific antibody drugs clinically used for the prevention and treatment of CLL1-targeted diseases (such as acute myeloid leukemia, myelodysplastic syndrome, or chronic myeloid leukemia), as well as to produce CLL1-targeting CAR cells and CLL1 protein detection kits. The single-domain antibody drug of the present invention has a stable structure, small molecule, is easily recombinantly expressed, and is inexpensive to produce. It can be used alone or as a drug delivery system for delivering related drugs, and has very broad prospects and important significance in fields such as pharmaceutical applications and clinical diagnosis.

The invention relates to the field of medical auxiliary instruments, in particular to a multi-mode upper limb correction exerciser. The device mainly comprises a correction vest, a main control unit and upper limb rehabilitation executing mechanisms which are symmetrically arranged. The executing mechanism is composed of a large arm supporting plate and a small arm supporting plate which are connected in series through a hinge, and a bearing air bag on the inner side of the executing mechanism is provided with an electrical stimulation and targeted drug delivery module. Each treatment unit of a microneedle electrode array in the electrical stimulation and targeted drug delivery module adopts a positive and negative microneedle group partition layout, and a directional electric field can be formed subcutaneously in combination with positive and negative electrode micro liquid medicine cavity groups which are isolated from each other and are internally communicated, so that drug ions with different charges can be driven to efficiently transdermal along a definite path. The mechanical medicine supply pump is linked with the joint hinge, and limb movement is converted into pumping power. And the main control unit intelligently coordinates electrical stimulation and drug administration to realize synchronous treatment. According to the invention, the coordination of electrical stimulation, iontophoresis administration and rehabilitation exercise is realized, and the drug transdermal efficiency, the treatment targeting and the overall rehabilitation effect are remarkably improved.

Provided herein are nucleic acid sequences for targeting one or more single point mutations within a target gene, wherein the target gene is one or more tumour suppressor genes; wherein the tumour suppressor gene is p53; and methods of treating cancer in a subject comprising administering the same.

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM-1 antibody to a nanoparticle. The composition may be used as an imaging agent and / or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

Provided is a therapeutic agent for spinal cord injury from an acute phase to a subacute phase that has heretofore been difficult to treat, in particular, severe spinal cord injury. The therapeutic agent for spinal cord injury from an acute phase to a subacute phase includes the following: (1) (a) a hepatocyte growth factor protein or a substance having a c-Met phosphorylation action comparable to that of the hepatocyte growth factor protein, or (b) a gene encoding the hepatocyte growth factor protein or a gene encoding the substance having a c-Met phosphorylation action comparable to that of the hepatocyte growth factor protein; and (2) a pluripotent stem cell.